WisdomTree BioRevolution Fund (WDNA) seeks to track the WisdomTree BioRevolution Index, which measures companies driving innovation in biotechnology, genomics, precision medicine, and life sciences technology. This thematic equity ETF provides exposure to global companies developing revolutionary treatments, diagnostic tools, and healthcare technologies.
How It Works
WDNA uses a passively managed, modified market-capitalization-weighted approach that tracks its underlying index. The fund selects companies based on revenue exposure to biorevolution themes including gene therapy, immunotherapy, digital health, and medical devices. Holdings are weighted by market cap with modifications to ensure diversification across biorevolution sub-themes. The portfolio rebalances semi-annually to capture emerging companies and maintain thematic focus across approximately 50-100 global biotechnology and life sciences stocks.
Key Features
- Pure-play exposure to biorevolution theme including gene therapy, CRISPR technology, and precision medicine companies often missed by broad healthcare ETFs
- Global diversification across developed markets captures innovation leaders beyond just U.S. biotech companies
- Launched in 2021 to capitalize on accelerated healthcare innovation trends emerging from COVID-19 pandemic
Risks
- This ETF can lose value significantly during biotech sector downturns, potentially declining 40-60% when clinical trials fail or regulatory approvals are delayed
- High concentration in early-stage companies means individual stock failures can materially impact fund performance due to limited diversification
- Thematic investing risk means the biorevolution trend could lose investor favor, leading to sustained underperformance versus broader market indices
Who Should Own This
Best suited as a satellite holding (5-15% of equity allocation) for aggressive growth investors with 7+ year time horizons and high risk tolerance. Appropriate for investors seeking exposure to healthcare innovation trends and comfortable with biotech sector volatility. Works well for younger investors in tax-advantaged accounts who can withstand significant short-term fluctuations.